Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CANF | US
0
0%
Healthcare
Biotechnology
31/12/2023
17/10/2024
2.70
2.70
2.80
2.48
Can-Fite BioPharma Ltd. a clinical-stage biopharmaceutical company develops small molecule therapeutic products for the treatment of cancer liver inflammatory diseases and erectile dysfunction. The company's lead drug candidate Piclidenoson which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602 which is in pre-clinical trial for the treatment of erectile dysfunction. In addition the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop manufacture and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer inflammatory autoimmune and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva Israel.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
94.6%1 month
82.9%3 months
91.8%6 months
89.5%-
3.30
5.53
0.01
0.00
0.10
13.36
-
-7.79M
16.46M
16.46M
-
-1.30K
-
-19.40
-157.62
2.51
5.94
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.93
Range1M
0.97
Range3M
2.82
Rel. volume
0.55
Price X volume
211.49K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Minerva Neurosciences Inc | NERV | Biotechnology | 2.58 | 18.04M | -3.37% | n/a | -194.60% |
Cognition Therapeutics Inc. Common Stock | CGTX | Biotechnology | 0.4456 | 17.88M | -0.49% | n/a | 2.71% |
Inhibikase Therapeutics Inc. | IKT | Biotechnology | 2.35 | 17.54M | 21.13% | n/a | 3.49% |
Kazia Therapeutics Limited | KZIA | Biotechnology | 0.5269 | 17.54M | 58.04% | n/a | 6.82% |
Athira Pharma Inc | ATHA | Biotechnology | 0.4477 | 17.21M | -1.52% | n/a | 1.69% |
GeoVax Labs Inc | GOVX | Biotechnology | 2.01 | 17.15M | -4.29% | n/a | -6.03% |
ICU | ICU | Biotechnology | 4.02 | 16.85M | -4.29% | n/a | -45.50% |
IN8bio Inc. Common Stock | INAB | Biotechnology | 0.2301 | 16.69M | 0.52% | n/a | 43.30% |
Synlogic Inc | SYBX | Biotechnology | 1.42 | 16.61M | -1.39% | n/a | 0.00% |
Evaxion Biotech A/S | EVAX | Biotechnology | 2.71 | 15.99M | 0.00% | n/a | 837.11% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.10 | 0.53 | Cheaper |
Ent. to Revenue | 13.36 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 5.53 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 91.84 | 72.92 | Riskier |
Debt to Equity | 0.01 | -1.24 | Expensive |
Debt to Assets | 0.00 | 0.25 | Cheaper |
Market Cap | 16.46M | 3.78B | Emerging |